BMJ’s Pradaxa Exposé Includes Wider Call For Monitoring Of All New Anticoagulants
This article was originally published in The Pink Sheet Daily
Executive Summary
British Medical Journal investigation focuses mainly on Boehringer’s direct thrombin inhibitor Pradaxa, but also suggests that all novel anticoagulants could benefit from testing to ensure the right anticoagulant dose is being given, for safety’s sake.
You may also be interested in...
Novel Anticoagulants Need Blood Level Monitoring Measures, FDA’s Temple Says
Although coagulation level monitoring would negate the newer drugs’ convenience advantage over warfarin, FDA reviews of Daiichi’s Savaysa suggest a tailored dosing approach is needed to optimize antithrombotic benefits against bleeding risks.
Edoxaban Review Spurs FDA Call For Changes In Anticoagulant Trials
Agency staff recommend separate assessment of ischemic and hemorrhagic strokes, and exposure-targeting of therapeutic blood levels; cardio-renal panel endorses Daiichi Sankyo’s Factor Xa inhibitor for atrial fibrillation, but concerns about reduced efficacy in normal renal function patients may result in a competitively disadvantaged label.
FDA’s Pradaxa Review Overemphasized Efficacy, Safety Experts Argue
Critique in the British Medical Journal of FDA’s review of Boehringer Ingelheim’s anticoagulant concludes agency should have approved a low-dose version, touching off a classic drug safety debate about the value of encouraging use of a potentially risky product.